PTGS2 and breast carcinoma: Taken together, these findings demonstrate that combined treatment of γ-tocotrienol with PPARγ antagonists displays synergistic anticancer activity by PPARγ-independent mechanisms primarily by decreasing expression of COX-2 and prostaglandin synthesis in breast cancer cells.